Last edition
News about
Hope Medicine Reports Positive Phase II Results for First-in-Class Endometriosis Drug
HMI-115 shows significant pain reduction without hormonal disruption, paving the way for global phase III trials.
UK Regulator Pushes Shift Toward Reduced Animal Testing, Issues Roadmap for Alternative Methods
The UK’s medicines regulator, the Medicines and Healthcare products Regulatory Agency, has outlined new guidance aimed at reducing reliance on animal testing and accelerating the adoption of alternative scientific methods in drug development.
Endogenex Raises USD 50 Million to Advance Novel Diabetes Treatment
Series C extension led by Arboretum Ventures to fund pivotal clinical study and support regulatory pathway for ReCET System.
Royal Philips Tops EPO MedTech Patent Rankings, Reinforces Innovation Leadership
Royal Philips has secured the top position among medical technology companies in the European Patent Office’s (EPO) Technology Dashboard 2025, underscoring its continued leadership in health technology innovation.
Neuberg Diagnostics Launches Blood-Based Test for Early Alzheimer's Detection
Neuberg Diagnostics, Chennai, has introduced Mispa i60, a simple blood-based test designed to detect early signs of Alzheimer’s disease, offering a non-invasive and cost-effective screening solution.
Artelo Biosciences Expands ART27.13 as Companion Therapy to GLP-1 Treatments
Artelo Biosciences advances ART27.13 as a potential companion therapy to GLP-1 treatments, aiming to preserve muscle mass during weight loss, supported by new preclinical studies, patent filings and published research.
LB Pharmaceuticals Starts Phase 3 Trial for LB-102 in Schizophrenia
LB Pharmaceuticals initiates Phase 3 NOVA-2 trial of LB-102 for schizophrenia, enrolling ~460 patients to assess PANSS score, symptoms and safety, with topline results expected in 2H 2027.
IMUNON Reports Phase 2 Data Showing Improved Survival in Advanced Ovarian Cancer
IMUNON reports updated Phase 2 data showing improved Overall Survival (OS) with IMNN-001 in advanced ovarian cancer.
Denali Therapeutics Wins FDA Approval for AVLAYAH in Hunter Syndrome
US FDA approves Denali Therapeutics’ AVLAYAH for Hunter syndrome (MPS II), the first new treatment in nearly 20 years and a novel biotherapeutic designed to cross the blood-brain barrier.
Alteogen and Biogen Sign Deal for Hybrozyme-Based Subcutaneous Biologics
Alteogen signs a licensing deal with Biogen to develop and commercialise Hybrozyme-based subcutaneous biologics, granting rights for two products using the ALT-B4 platform.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy